Analysis of the clinical efficacy of ensifentrine-Ohtuvayre in the effective treatment of patients with chronic obstructive pulmonary disease

Ensifentine (Ensifentrine, Ohtuvayre) is a new dual phosphodiesterase inhibitor (PDE3/4inhibitor Preparation), by simultaneously inhibiting PDE3 and PDE4, increasing the concentration of cyclic adenosine monophosphate (cAMP) in bronchial smooth muscle, thereby exerting bronchodilator and anti-inflammatory effects. This unique mechanism enables it to have a dual effect in patients with chronic obstructive pulmonary disease (COPD), which can both improve lung function and relieve inflammation-related symptoms.

Clinical trials have shown that exefantine can significantly improve COPD patients’ forced expiratory volume (FEV1) and improve airway patency. Compared with placebo, patients treated with Ohtuvayre experienced significant improvements in lung function indicators, reduced dyspnea and wheezing symptoms, and improved exercise tolerance after short-term use. This suggests that exefentine may be an effective agent in the acute and daily management of COPD exacerbations.

In terms of symptom improvement and quality of life, patients reported that symptoms such as chronic cough, sputum production, and dyspnea were alleviated and their ability to perform daily activities was improved after using ensefentine. The study also found that Ohtuvayre can reduce the frequency of acute exacerbations of COPD during maintenance treatment, especially for patients with moderate to severe COPD, especially those who do not respond well to traditional inhaled bronchodilators or glucocorticoids.

Overall, exefentine (Ohtuvayre) has shown significant lung function improvement and symptom relief in the treatment of COPD, and its dual mechanism provides a complementary option to traditional drugs. However, this drug is not yet on the market in China. Clinical use must be obtained through formal channels under the guidance of professional doctors, and must be combined with inhaled bronchodilators and other standard treatment options to achieve individualized and long-term management treatment goals.

Reference link:https://www.drugs.com